


Optum

2025 InterQual® Criteria updates

Centene

March 14, 2025



Release Resources

- Clinical revisions available on the IQ Resource Center [InterQual® Resource Center](#)
- Demo recordings will be posted to the Resource Center next week
- 2025 criteria available in InterQual Integ environment

Global Update



 Removed CMS GMLoS benchmarks from software. These benchmarks are available in Clinical Reference

Behavioral Health

Adult and Geriatric Psychiatry, Child and Adolescent Psychiatry, and Substance Use Disorders



Global changes

- Citations for key sources were updated including:
 - Association for Ambulatory Behavioral Healthcare (AABH)
 - Commission on Accreditation of Rehabilitation Facilities (CARF)
 - Joint Commission
- Frequency associated with establishing/reviewing a treatment plan review was removed. The timing of treatment planning is based on clinical factors, not routine time requirements

Weight-gain-specific treatment plan, All:

Accompanied or monitored bathroom visits	x	🗨
Nutritional assessment daily	x	🗨
Re-evaluation of plan effectiveness daily	x	🗨
Supervised meals and snacks	x	🗨
Vital signs at least 3 times in 24 hours	x	🗨



Weight-gain-specific treatment plan, All:

Accompanied or monitored bathroom visits	x	🗨
Nutritional assessment daily	x	🗨
Re-evaluation of plan effectiveness	x	🗨
Supervised meals and snacks	x	🗨
Vital signs at least 3 times in 24 hours	x	🗨

Behavioral Health Services



Applied Behavior Analysis (ABA) Program:

- Based on the Council of Autism Service Providers (CASP), Version 3, 2024, Practice Guideline, we now include recommendations related to ABA assessment:
 - For initiation, if an initial assessment has not been completed- added a recommendation for “Initial Applied Behavior Analysis Assessment, up to 20 hours”
 - For continuation, added a recommendation for reassessment if it's been more than 6 months since the last assessment
- In the child criteria, removed the specific age requirement for schooling as state mandates do not align on the age that a child should attend school. Criteria changed to:
 - “Not enrolled in school or preschool or early intervention program and compulsory school age”
 - “Not enrolled in school and compulsory school age”

Behavioral Health Services



Neuropsychological and Developmental Testing:

- Updated hours for testing to “up to 8 hours” for all recommendations
- Removed recommended hours from Limited Evidence recommendations. This change was made to allow for individualized planning.

Recommended *Limited evidence, additional review required.*

Neuropsychological and Developmental Testing

Ltd

2nd

Up to 6 hours - Outpatient

Show codes

Note

→

Recommended *Limited evidence, additional review required.*

Neuropsychological and Developmental Testing

Ltd

2nd

Show codes

Note

Behavioral Health Services



Electroconvulsive Therapy (ECT)

- Parkinson's disease has been retired as an indication for ECT as this is not a commonly used indication for this procedure

Behavioral Health Services



Psychological Testing

- Removed specific tests in recommendations and updated to “Psychological Testing” to reflect real world practice
- Updated time approved for testing to “up to 8 hours” for all recommendations

Psychological testing, Minnesota Multiphasic Personality Inventory-2® (MMPI-2®)	- Up to 2 hours - Outpatient	Show codes
Or		
Psychological testing, Personality Assessment Inventory™ (PAI®)	- Up to 2 hours - Outpatient	Show codes
Or		
Psychological testing, Minnesota Multiphasic Personality Inventory-3® (MMPI-3®)	- Up to 2 hours - Outpatient	Show codes



Psychological testing	- Up to 8 hours	Show codes
-----------------------	-----------------	----------------------------

Behavioral Health Services



Transcranial Magnetic Stimulation (TMS):

Retired the following indications for TMS because they are not commonly used indications for this procedure:

- Amyotrophic lateral sclerosis or motor neuron disease
- Epilepsy
- Parkinson disease
- Tinnitus

Acute global changes

InterQual® Site of Service

InterQual Inpatient List setting updates

- The Inpatient List will be CPT code based and include codes addressed within the InterQual Procedures content. It will include all settings including Inpatient, Outpatient, No setting determined
- It has been renamed to “InterQual Procedures setting by CPT® code report”

InterQual® Procedures Criteria						
2024® Procedures setting by CPT code report						
Release Date: March 21, 2025						
Confidentiality Notice: This document is for the sole use of its intended recipients and may contain confidential, proprietary and/or privileged information of Optum and/or its subsidiaries. Any unauthorized review, use, disclosure or distribution is prohibited.						
Guideline description	Recommendation description	Code	Code description	Age	Adult setting	Pediatric setting
Ablation of Excision, Endometriosis, Laparoscopic	Ablation of Excision, Endometriosis, Laparoscopic	5862	LAPAROSCOPIC, SURGICAL, WITH FULGURATION OR EXCISION OF LESIONS OF THE OVARY, PELVIC VISCERA, OR PERITONEAL SURFACE BY ANY METHOD	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7370	LAPAROSCOPIC, SURGICAL, ABLATION OF 1 OR MORE LIVER TUMORS(S), RADIOFREQUENCY	Adult	No Setting Determined	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7371	LAPAROSCOPIC, SURGICAL, ABLATION OF 1 OR MORE LIVER TUMORS(S), RADIOFREQUENCY	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7380	ABLATION, OPEN, OF 1 OR MORE LIVER TUMORS(S), RADIOFREQUENCY	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7381	ABLATION, OPEN, OF 1 OR MORE LIVER TUMORS(S), CRYOSURGICAL	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7382	ABLATION, OPEN, OF 1 OR MORE LIVER TUMORS(S), PERCUTANEOUS, RADIOFREQUENCY	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7383	ABLATION, 1 OR MORE LIVER TUMORS(S), PERCUTANEOUS, CRYOABLATION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7389	UNLISTED PROCEDURE, LIVER	Adult	No Setting Determined	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	7399	ULTRASOUND GUIDANCE FOR, AND MONITORING OF, PARENCHYMAL TISSUE RE-ABLATION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	6840	RE-ABLATION 1+TUMORS PER ORGAN VIVAG GUN P20	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	6807	RE-ABLATION 1+TUMORS PR ORGAN W/FLUORISMS G801 ON	Adult	No Setting Determined	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743	VASCULAR EMBOLIZATION OR OCCLUSION, INCLUSIVE OF A.I. RADIOLOGICAL SUPERVISION AND INTERSTATION INTRACARDIAC/CEPHALIC ROADMAPING AND ORGAN SCHEMIA, OR INFARCTION	Adult	Outpatient	
ablation or Transcatheter Therapy, Liver	Abative Therapy, Liver	5743</				

Acute Adult

Global changes



Removed

- Removed the endpoint $\leq 2d$ from Oxygen $\geq 40\%$ in Intermediate
- Removed BP values specific to chronic hypertension from hemodynamic instability findings at critical



Updated

- Expanded Care Management Information (CMI) notes across multiple subsets, including adding Admission Consideration notes to existing CMI notes that did not previously include them
- Immunocompromised note to include Primary and secondary immunodeficiency

Acute Adult Criteria

At Observation level of care:

- Non-obstructive acute kidney injury and, Both:**

Obstructive acute kidney injury, post treatment and, Both:

Note:

Creatinine, Both:

$\geq 1.5x$ to $< 3x$ baseline or estimated baseline

$< 4mg/dL$

IV fluid

☐ Obstructive acute kidney injury, post treatment and, **All:**

☒ High risk, ≥ One:

Bilateral ureteral obstruction with bilateral hydronephrosis

Solitary kidney ☒

Transplanted kidney ☒

Creatinine ≥ 1.5x baseline or estimated baseline ☒

IV fluid ☒

Acute Adult




Arrhythmia: Atrial

At the Observation level of care:

- Added criteria for antiarrhythmic with no proarrhythmic risk
- Moved the Non-responder criteria to episode day 2

Observation



Intermediate



Acute Adult and Pediatric

Bowel Obstruction

Adult and Pediatric

- Added Observation level of care
- At the Acute level of care, added water-soluble contrast study as a type of imaging study

Adult

- The number of episode days was changed from 4 days to 5 days

Pediatric

- At Observation level of care, added criteria for intussusception with an air or water enema performed and IV fluid

OBSERVATION, One:

Bowel obstruction suspected requiring NPO and IV fluid

ACUTE, One:

Bowel obstruction confirmed by imaging (including water-soluble contrast study) and, **Both:**

NG tube to suction

IV fluid

- At the Observation and Acute levels of care, streamlined criteria by moving initial treatment requirements into a note
- O₂ sat was changed from $\leq 91\%$ to $\leq 89\%$ on episode days 3 & 4 at Acute level of care to address non-symptomatic patients with significant hypoxia who need additional treatment



Optum

Acute Adult



Diabetic Ketoacidosis

- At the Observation level of care, clarified the criteria by adding (includes SC) to the insulin intervention
- At the Observation and Critical levels of care, decreased the glucose threshold from to 250 mg/dL to 200 mg/dL
- At the Critical level of care added criteria for:
 - Euglycemic diabetic ketoacidosis
 - Mixed diabetic ketoacidosis and hyperglycemic hyperosmolar state

☐	CRITICAL, Both:	☐	☐
☐	Hyperglycemic crisis, One:	☐	☐
☐	Diabetic ketoacidosis, ≥ One:	☐	☐
☐	Euglycemic diabetic ketoacidosis, All:	☐	☐
☐	Mixed diabetic ketoacidosis and hyperglycemic hyperosmolar state, All:	☐	☐
☐	Intervention, Both:	☐	☐

Acute Adult

General Medical



Observation

Severe pain:

- Removed requirement of 2 doses of analgesic prior to admit
- Changed intervention from analgesic ≥ 2 doses to 2-3x/24h
- Moved the Non-responder criteria to episode day 3

Moved the Non-responder criteria to episode day 3 for:

- Danger to self or others
- Spinal Headache

Pain, severe, Both: 	
Unresponsive to ≥ 2 doses of analgesic prior to admit decision	 
 Intervention, Both: 	
Requiring additional analgesic ≥ 2 doses  	
Pain assessment at least every 4h   	

Pain, severe and failed outpatient analgesic and, One:
Analgesic 2-3x/24h  



Acute Adult



General Medical - Genitourinary

Observation:

Renal calculus:

- On episode day 1, removed imaging requirement
- Removed IV fluid requirement
- Moved the Non-Responder criteria to episode day 3

Urinary tract obstruction/hydronephrosis:

- Added uncomplicated urinary tract obstruction to admission and continued stay
- Added criteria for postobstructive diuresis on episode day 1

Acute (admission):

- Added high risk factors to urinary tract obstruction to differentiate the Acute and Observation levels of care

Acute (continued stay):


- On episode day 3-X, removed criteria for elevated creatinine. This complication can be managed in the Acute Kidney Injury subset
- Added postobstructive diuresis as a complication on episode days 2 and 3

Acute Adult

General Surgical

At the Acute level of care

- Added short stay within the last 2 days to post-op day 1
- On operative day, added pregnancy and appendicitis as high-risk factor
- Added pre-operative infection and anti-infective (excludes prophylactic) ≤ 7 days since initiation to post-op days 1-22



Notes

Informational Note
Examples of procedures designated as short stay include:

- Carotid artery stent, transcatheter placement
- Carotid endarterectomy (CEA)
- Lumbar fusion
- Roux-en-Y gastric bypass
- Video-assisted thoracoscopy (VAT)

This list is not intended to be all inclusive.

Short stay within the last 2d

Moderate stay within the last 5d

Long stay within the last 6d

Post external fixation of open fracture awaiting internal fixation $\leq 5d$

Pre-operative infection and anti-infective (excludes prophylactic) $\leq 7d$ since initiation

Solid organ transplant, ≥ 1 One:

Post surgery or invasive procedure and complication, ≥ 1 One:

Acute Adult

General Trauma

At the Acute level of care, added a note to define “traumatic injury”

Episode Day 1, One: 2MN

Symptom or finding within 24h

OBSERVATION, ≥ One:

ACUTE, ≥ One:

General, ≥ One:

Bleeding and anticoagulation

Traumatic injury

Age ≥ 65

Finding, ≥ One:

Traumatic injury

Traumatic injuries include, but are not limited to the following:

- Chest trauma with normal or unchanged electrocardiogram (ECG) and normal or at baseline troponin
- Chest wall fractures (e.g., rib(s), sternal, or scapula)
- Dislocation of major joint prosthesis
- Fractures of the ankle, femur, hip, or pelvis (e.g., osteoporotic fractures related to trauma)
- Fracture or dislocation of the spine (e.g., compression fractures of spine related to trauma)
- Pneumothorax or hemothorax from chest wall injuries
- Suspected abdominal organ injury (e.g., liver, spleen)
- Head trauma with negative head computed tomography (CT) scan in the setting of anticoagulation or antiplatelet use, cognitive impairment, and/or GCS 13-14 and less than baseline

Mainnutrition

Polypharmacy, ≥ 5 chronic medications

Acute Adult



Heart Failure

- At the Observation level of care O₂ sat was removed as a finding
- At the Acute level of care, changed O₂ sat < 89% to O₂ sat < 90%



Acute Adult



Hyperglycemic Hyperosmolar State

- Blood glucose, pH, and bicarbonate criteria updated

CRITICAL, ≥ One:

Hyperosmolar hyperglycemic state (HHS), Both:

Care

Finding, All:

Arterial or venous pH > 7.30 or serum HCO₃ or CO₂ > 18 mEq/L(18 mmol/L)

Blood glucose > 600 mg/dL(33.3 mmol/L)

Serum osmolality > 320 mOsm/kg(320 mmol/kg)

Insulin, continuous and IV fluid resuscitation



CRITICAL, ≥ One:

Hyperglycemic hyperosmolar state (HHS), Both:

Care

Absence of significant ketosis and, All:

Blood glucose ≥ 600 mg/dL(33.3 mmol/L)

Arterial or venous pH ≥ 7.30

Serum HCO₃ or CO₂ ≥ 15 mEq/L(15 mmol/L)

Serum osmolality > 320 mOsm/kg(320 mmol/kg)

Insulin, continuous and IV fluid resuscitation

Acute Adult



Hypertension

- At the Observation level of care, diastolic blood pressure was updated from > 120mmHg to > 110mmHg

OBSERVATION, All:

Hypertensive urgency and post treatment blood pressure, $\geq$ One:

Systolic > 180 mmHg

x

Diastolic > 120 mmHg

x



OBSERVATION, All:

Hypertensive urgency and post treatment blood pressure, $\geq$ One:

Systolic > 180 mmHg

x

Diastolic > 110 mmHg

x

Acute Adult



Infection: Endocarditis

- At the Critical level of care, added criteria for a history of congenital heart disease, prosthesis, implanted material, or implanted device to allow for monitoring of high-risk patients

CRITICAL, ≥ One: 

History of congenital heart disease ≤ 2d



History of cardiac prosthesis, implanted material, or implanted device ≤ 2d



AKI and, Both:



Arrhythmia, ≥ One:



CRRT



- At the Acute level of care, updated findings for severe ulcerative colitis flare

Acute

	Ulcerative colitis, acute flare and, Both:
	≥ 6 bloody stools within the last 24h and, ≥ One:
	CRP > 30 mg/L(3 mg/dL)
	ESR > 30 mm/h
	Hb < 10.5 g/dL(105 g/L)
	Heart rate > 90 bpm, sustained
	Temperature > 100.0°F(37.8°C)

Acute Adult



Pancreatitis

- Updated the number of episode days from 4 days to 5 days
- At the Acute level of care, added criteria for:
 - Patients with chronic pancreatitis experiencing an acute flare, or acute flare during current hospitalization
 - Local complication of pancreatitis (necrosis, walled off necrosis, pseudocyst and fluid collection)
 - High-risk factors for acute pancreatitis
- At the Observation and Acute levels of care, added goal directed IV fluid resuscitation for acute pancreatitis on episode day 1
- At the Critical level of care:
 - Added hypertriglyceridemia-induced pancreatitis

Acute Adult



Stroke

- At the Critical level of care on episode day 1, added criteria for Subarachnoid hemorrhage requiring frequent neurological assessment

CRITICAL, ≥ One:			
Subarachnoid hemorrhage and neurological assessment every 1-2h			

Stroke and TIA

- At the Acute level of care, added PR as route for anti-platelet and anti-coagulant administration

ACUTE, One:			
Suspected acute stroke, All:			
New and persistent neurological deficit, ≥ One:			
CT or MRI performed			
Antiplatelet agent or anticoagulant (includes PO and PR), administered or contraindicated			

Acute Pediatric Criteria

Acute Pediatric



Dehydration or Gastroenteritis

- At the Acute level of care:
 - Changed listlessness or lethargy to mental status change (excludes coma, stupor, or somnolence)
 - Sodium threshold updated from 146-158 mEq/L to 151-158 mEq/L
- At the Critical level of care, updated Bicarbonate ≤ 17 mEq/L to serum HCO₃ or CO₂ ≤ 15 mEq/L

ACUTE, Both: ☐ ☐ ☐

Finding, $\geq$ One: ☐ ☐ ☐

Age ≤ 1 yr and symptomatic ☐ ☐ ☐

Listlessness or lethargy ☒ ☐ ☐

Chloride $<$ lower limit of normal or $>$ ULN ☐ ☐ ☐

Potassium 2.5-3.2 mEq/L (2.5-3.2 mmol/L) and no ECG changes ☐ ☐ ☐

Sodium 146-158 mEq/L (146-158 mmol/L) ☒ ☐ ☐



ACUTE, Both: ☐ ☐ ☐

Finding, $\geq$ One: ☐ ☐ ☐

Age ≤ 1 yr and symptomatic ☐ ☐ ☐

Mental status change (excludes coma, stupor, or somnolence) ☒ ☐ ☐

Chloride $<$ lower limit of normal or $>$ ULN ☐ ☐ ☐

Potassium 2.5-3.2 mEq/L (2.5-3.2 mmol/L) and no ECG changes ☐ ☐ ☐

Sodium 151-158 mEq/L (151-158 mmol/L) ☒ ☐ ☐

Note ☐

Acute Pediatric

General Medical – Kawasaki

Observation

- Moved criteria for suspected Kawasaki disease to Observation

Acute

- Removed antiplatelet criteria for treatment of confirmed Kawasaki diagnosis

Intermediate and Critical

- Added criteria for additional work up and intervention of cardiac dysfunction related Kawasaki disease

Continued stay

- Added criteria for treatment of refractory Kawasaki disease including corticosteroids and immunomodulator therapy and post-treatment temperature monitoring



OBSERVATION, ≥ One:	
Kawasaki disease, suspected and, One:	
Age > 29d and, All:	Note
Temperature ≥ 100.4°F (38.0°C) for ≥ 5d	x
Finding, ≥ Two:	
Bilateral conjunctivitis without exudate	x
Cervical lymphadenopathy	x
Changes in lips or oral cavity	x
Edema or erythema of hands or feet	
Rash:	x
Echocardiogram performed within 24h	x
Age > 29d to ≤ 6 mos and, Both:	Note
Temperature ≥ 100.4°F (38.0°C) for ≥ 7d	x
Echocardiogram performed within 24h	x

Acute Pediatric



General Medical – Genitourinary

- Genitourinary obstruction is now Urinary tract obstruction and includes hydronephrosis

Observation:

- Added uncomplicated urinary tract obstruction to admission and continued stay
- Removed IV fluid for renal calculus without obstruction as IV analgesic is driver
- Moved Non-Responder criteria to episode day 3

Acute:

- Added high-risk factors
- Added ureteral stent placement as a treatment option

Continued stay:

- Added criteria for urinary tract obstruction with potential complications at Observation and Acute levels of care
- Obstructive AKI and postobstructive diuresis added to Acute level of care

Acute Pediatric



Infection: Cellulitis

- The number of episode days was changed from 3 days to 4 days
- Moved Observation Non-responder criteria to episode day 3
- Observation level of care:
 - Updated terminology for animal or human bite to atypical infection
 - Added perianal and perineal regions as affected sites of cellulitis
- Acute level of care:
 - Updated complicated cellulitis to include systemic signs/symptoms and high-risk patients
 - Update orbital cellulitis to include subperiosteal or orbital abscess

Acute Pediatric



Infection: Endocarditis

- The number of episode days was changed from 22 days to 15 days
- Removed Modified Duke criteria and differentiation between acute and subacute endocarditis throughout
- Critical level of care:
 - Added cerebral embolic event and neurological assessment on episode day 1
 - Added criteria for a history of congenital heart disease, prosthesis, implanted material, or implanted device to allow for monitoring of high-risk patients
- At the Intermediate and Critical levels of care on episode days 2-14, added cerebral embolic event and neurological assessment

Acute Pediatric



Infection: GI/GYN

Observation:

- Added suspected appendicitis criteria

OBSERVATION, One:   		
	Appendicitis, suspected and, Both:	  
	Abdominal pain and, ≥ One:	  
Anorexia   		
Cough, hop, or percussion tenderness		
Migration of pain   		
Nausea or vomiting   		
Temperature ≥ 100.4°F (38.0°C)   		
WBC ≥ 10,000/cu.mm (10x10⁹/L)   		
	Intervention, ≥ One:	
Anti-infective   		
NPO and IV fluid   		

Acute:

- Added appendicitis and nonoperative management criteria

ACUTE, ≥ One:   		
	Appendicitis and nonoperative management, Both:	  
Appendiceal abscess or phlegmon by imaging   		
Anti-infective   		

Acute Pediatric



Infection: Pyelonephritis or Complex UTI

- Name change from Infection: Pyelonephritis
- At the Acute level of care:
 - Removed WBC as a finding of unresolved pyelonephritis on episode day 2
 - Added “PO anti-infective AND IV fluid” as an intervention
 - Added criteria for multidrug resistant bacteria on episode days 2 and 3

Acute Pediatric



Pancreatitis

- At the Acute level of care:
 - Moved “Chronic pancreatitis” from General Medical to Pancreatitis
 - Added goal directed IV fluid resuscitation for acute pancreatitis on episode day 1
 - Added local complication of pancreatitis (necrosis, walled off necrosis, pseudocyst and fluid collection)
 - Added criteria for patients with chronic pancreatitis who are experiencing acute flare during current hospitalization
 - On episode day 2, added ERCP as an intervention for biliary obstruction
- At the Intermediate level of care, added criteria for hypoxic patients who require supplemental oxygen
- At the Intermediate and Critical levels of care, added criteria for patients on chronic ventilation who require an increase in ventilatory support

Post Acute (SAC/SNF)

Post-Acute



Subacute Care/Skilled Nursing Facility

- **Added Maintenance Therapy and Nursing Criteria** for admission and continued stay of Medicare beneficiary to allow for patients who may not have the potential to improve but need inpatient skilled services to maintain their current status or slow deterioration
- Admission criteria for maintenance is intended to capture patients who might initially have weight bearing limitations (for example s/p lower extremity ORIF) but need therapy to maintain functional status and prevent decline. Once limitations are lifted, a review would be completed using continued stay criteria under “rehabilitative or restorative therapy with progress anticipated”.
- New notes were added to the maintenance criteria to further explain and detail the intent, including instructional type notes which indicate when the application of the criterion is appropriate
- Responder criteria were updated to reflect the patient who was on a maintenance therapy and/or maintenance nursing plan of care and is now appropriate for discharge

Post-Acute



Subacute Care/Skilled Nursing Facility

- **Extended Episode Weeks:** The number of episode weeks has been extended to 16 weeks to accommodate patients who may have longer stays while receiving maintenance skilled therapy or nursing services and to align with Medicare guidelines. The length of stay for patients receiving rehabilitative therapy or nursing remains unchanged.
- **Custodial care:** Admission consideration note added to Admission and Preadmission reviews

Post-Acute



Home Care

- Home health aide pathway now includes continued service beyond 120 days after start of care

Home health aide, Choose one: *Required*  

☐ Review for services within first 30 days of care

☐ Continued services requested for subsequent 30 days of care

☐ Continued services 60 to 120 days after start of care

☒ Continued services beyond 120 days after start of care 

Other clinical information (add comment)

Home health aide, Choose one: *Required*  

☐ Review for services within first 30 days of care

☐ Continued services requested for subsequent 30 days of care 

☐ Continued services 60 to 120 days after start of care

Other clinical information (add comment)



Procedures

InterQual® Site of Service

InterQual setting updates

- Setting determinations moving from the recommendation level to the review level
- InterQual settings will be sourced from a claims-based benchmark by CPT code
- Available settings: Inpatient, Outpatient, or No Setting Determined
- A setting may be flagged as Limited Data when we do not have a statistically meaningful volume of claims for that code
- To determine an appropriate setting the reviewer will select all of the CPT codes included on the authorization request
- Setting will appear in a new field on the review summary

InterQual Procedures content updates related to this change:

- Specific criteria addressing setting was removed from the following subsets:
 - Total Joint Replacement (TJR), Hip
 - Total Joint Replacement (TJR), Knee
 - Unicondylar or Patellofemoral Knee Replacement
 - Video EEG
- Specific setting notes were removed as they addressed clinical factors differentiated by coding

Impacts the following products

- LOC: Acute Adult (Inpatient List)
- LOC: Acute Pediatric (Inpatient List)
- BH: Behavioral Health Services
- CP: Procedures
- Medicare Procedures Navigator (CMS setting only)

InterQual® Site of Service

CMS setting updates

- Within InterQual Procedures, the reviewer will be able to toggle between IQ and CMS setting
- Medicare Procedures Navigator will only include settings based on CMS sources
- Available settings: *CMS Inpatient Only, CMS ASC eligible, CMS ASC excluded, No CMS Setting Available*

InterQual® Procedures – Site of Service

Recommendations

BENCHMARKS

Recommended

Evidence supports services as medically necessary.

Setting:

CMS ASC eligible

Source:

☐ InterQual

☒ CMS

Age:

☐ < 18

☒ ≥ 18

✓

Salpingo-Oophorectomy, Bilateral or Oophorectomy, Bilateral

Hide codes

SELECTED 1

ICD-10-CM

ICD-10-PCS

CPT®

Results Count: 5

CPT® only © 2011-2024 American Medical Association. All Rights Reserved

Medicare Procedures Navigator – Site of Service

Recommendations

Recommended

Evidence supports services as medically necessary.

Setting: CMS ASC eligible

✓

Percutaneous Coronary Intervention (PCI) - NGS

Hide codes

SELECTED 1

ICD-10-CM

CPT®

HCPCS

Results Count: 19

CPT® only © 2011-2024 American Medical Association. All Rights Reserved.

Code ↑	Description	Setting
92920	✓ PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, SINGLE MAJOR CORONARY ARTERY OR BRANCH	CMS ASC eligible
92921	PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY, EACH ADDITIONAL BRANCH OF A MAJOR CORONARY ARTERY (LIST SEPARATELY IN ADDITION TO ...	CMS ASC eligible
92924	PERCUTANEOUS TRANSLUMINAL CORONARY ATHERECTOMY, WITH CORONARY ANGIOPLASTY WHEN PERFORMED, SINGLE MAJOR CORONARY ARTERY OR B...	No CMS Setting Available
92925	PERCUTANEOUS TRANSLUMINAL CORONARY ATHERECTOMY, WITH CORONARY ANGIOPLASTY WHEN PERFORMED, EACH ADDITIONAL BRANCH OF A MAJOR C...	No CMS Setting Available
92928	PERCUTANEOUS TRANSCATHETER PLACEMENT OF INTRACORONARY STENT(S), WITH CORONARY ANGIOPLASTY WHEN PERFORMED, SINGLE MAJOR CORON...	CMS ASC eligible
92929	PERCUTANEOUS TRANSCATHETER PLACEMENT OF INTRACORONARY STENT(S), WITH CORONARY ANGIOPLASTY WHEN PERFORMED, EACH ADDITIONAL BRA...	CMS ASC eligible

Procedures



New subsets

- Hypoglossal Nerve Stimulation (HNS)
- Sacroiliac (SI) Joint Fusion
- Transplantation, Lung



Retired subsets

- Retired the following subsets, reviews can be completed in the Behavioral Health Services module:
 - Electroconvulsive Therapy (ECT)
 - Neuropsychological and Developmental Testing
 - Psychological Testing
 - Transcranial Magnetic Stimulation (TMS)
 - Urine Drug Testing (UDT) (and supporting benchmarks)



Procedures

Cardiology



Percutaneous Coronary Intervention (PCI)

- Added indication for cardiac allograft vasculopathy
- Added indication for staged intervention for non-infarct CAD following index PCI



- Expanded criteria to include asymptomatic patients who have an anatomic indication for revascularization

Procedures

Cardiology



Left Atrial Appendage Closure

-  Changed recommendation for pLAAC (Watchman device) from limited evidence to full recommendation for patients with atrial fibrillation, an increased risk of stroke, and a contraindication to anticoagulation
- Added criteria for sLAAC excision or exclusion performed concurrently with cardiac surgery with a full recommendation or limited evidence recommendation depending on the specific clinical scenario

Procedures

Cardiothoracic



Coronary Artery Bypass Grafting (CABG)

-  Added indication for staged intervention for non-infarct CAD following index PCI
- Removed myocardial viability testing as a requirement before recommending CABG for heart failure
- Expanded criteria to include asymptomatic patients who have an anatomic indication for revascularization

Procedures

General Surgery

Biopsy, Adrenal Mass, Needle

- Added a new indication for suspected adrenocortical carcinoma by imaging



Procedures

Oro-Maxillo-Facial, Dental & Otolaryngology

Orthognathic Surgery

- Combined criteria from 7 subsets into a new Orthognathic Surgery subset
 - Maxillectomy
 - Maxillomandibular Advancement
 - Osteotomy, Anterior Segment, Mandible
 - Osteotomy, Anterior Segment, Maxilla
 - Osteotomy, LeFort I
 - Osteotomy, Maxillary Buttress, +/- Mid Palatal Osteotomy
 - Osteotomy, Sagittal Split, Mandible Ramus
- Allows the reviewer to conduct a review for more than one procedure in the same review
- Additional scenarios provide more comprehensive coverage
- Expanded coding on the recommendation allows for flexibility in determining the most appropriate intervention



Procedures

Oro-Maxillo-Facial, Dental & Otolaryngology

Orthognathic Surgery (Pediatric)

- New subset addressing the following procedures:
 - LeFort I osteotomy
 - Bilateral sagittal split osteotomy



Procedures

Oro-Maxillo-Facial, Dental & Otolaryngology

Glossectomy, Partial or Hemiglossectomy

- ✂ • Removed indication obstructive sleep apnea (OSA)



Procedures

Podiatry



Osteotomy, Proximal Phalanx, First Toe +/- Bunionectomy



Hallux abductus interphalangeus without bunion

- Removed criteria for arthritis at metatarsophalangeal (MTP) joint

Hallux abductus without bunion

- Clarified the abnormality at distal articular set angle (DASA)
- Removed criteria for arthritis at proximal phalanx

Hallux valgus (bunion) at first metatarsophalangeal (MTP) joint

- Changed rule of Two to a rule of One for:
 - Moderate or severe hallux valgus angle (HVA) by imaging
 - Hallux valgus interphalangeal (HVI) angle abnormal by imaging

Procedures

Orthopedic, Upper Extremity

Arthrotomy & Arthroscopy or Arthroscopically Assisted Surgery, Shoulder

- Added new indications for proximal biceps (long head biceps tendon) and SLAP tears

Removal and Replacement or Revision, Joint Replacement, Shoulder:

- Removal and Replacement, Total Joint Replacement (TJR), Shoulder subset renamed to incorporate hemiarthroplasty
- Added hemiarthroplasty as an option for all indications
- Added new indications to support hemiarthroplasty:
 - Periprosthetic fracture by imaging
 - Failed rotator cuff tendon after index arthroplasty by imaging



Procedures

Neurosurgery



Decompression +/- Fusion, Cervical

- Added new indication for cervical kyphosis
- Added new limited evidence pathway for patients with severe pain who are unable to participate in PT

Decompression +/- Fusion, Cervical and Decompression +/- Fusion, Thoracic

- Updated imaging findings to “nerve or nerve root” to be more inclusive of how compression by imaging is reported
- Separated myelopathy indication into acute spinal cord compression and degenerative myelopathy with spinal cord compression to better differentiate urgent and non-urgent presentations
- Added myelomalacia as an imaging finding that supports spinal cord compression in degenerative cervical myelopathy

Procedures

Neurosurgery

Fusion, Cervical, Spine

- Added new limited evidence indication for atlantoaxial osteoarthritis

Artificial Disc Replacement, Cervical

- Added new indication for implant failure after prior disc replacement

Scoliosis or Kyphosis

- Added new indication for cervical kyphosis



Procedures

Specialized Procedures

Ablative or Transarterial Therapy, Liver

- Added indication for Intrahepatic cholangiocarcinoma for both ablative and transarterial therapy
- Added recommendation for transarterial therapy for the very early stage hepatocellular carcinoma pathway
- For hepatocellular carcinoma, added criteria for advanced stage
- For liver metastases from colorectal cancer:
 - Added a recommendation for transarterial therapy for chemotherapy refractory disease when surgery isn't feasible
 - Added a new pathway for planned as adjunct to surgery
- For liver metastases from neuroendocrine tumors, added criteria for “Planned as adjunct to curative resection”



Procedures

Specialized Procedures

Colonoscopy

- Expanded screening for colorectal cancer based on a positive family history to include a 3rd degree relative diagnosed with colorectal cancer at any age
- Added an option for Colonoscopy if stool DNA test (Cologuard) positive
- Added note to address new ACP guideline recommendation to begin colorectal cancer screening at age 50, which differs with other national guidelines that recommend age 45. No changes were made to criteria.



Procedures

Specialized Procedures

Sleep Studies

- Updated terminology from sleep apnea to sleep-related breathing disorder (SRBD)
- Restructured the suspected SRBD pathway to start with which type of disorder is suspected
- Aligned symptoms, findings, risk factors, and comorbidities with AASM's diagnostic criteria for each individual type of SRBD
- Added criteria to define obesity hypoventilation syndrome
- For both the suspected and known SRBD pathways:
 - Clarified when facility-based split-night sleep testing is appropriate
 - Updated recommendation options to allow choice between home sleep testing, where appropriate, or facility-based sleep testing (instead of just home sleep testing) to accommodate variations in practice patterns
- Added criteria for sleep studies following hypoglossal nerve stimulator implantation for both Adult and Pediatric subsets



Imaging

Imaging

Updates to Adrenal Content

Imaging, Abdomen and Pelvis

- Added new indication known adrenocortical carcinoma
- Under adrenal mass or incidentaloma, added criteria for known extra-adrenal malignancy and new adrenal mass
- Added more specific recommendations based on the size of indeterminate mass

Imaging Chest, Noncardiac

- Added suspected adrenocortical carcinoma as a primary cancer diagnosis for screening for lung metastases prior to treatment
- Added adrenocortical carcinoma as a diagnosis for restaging of primary cancer

Positron Emission Tomography (PET), Whole Body

- Added indication adrenal nodule or mass
- Added criteria for:
 - Suspected metastatic disease to adrenal gland
 - Suspected & known adrenocortical carcinoma



Imaging

Abdomen & Pelvis



Liver

- Added pediatric pathways for new liver mass by imaging and follow-up of benign liver mass
- Updated hepatocellular carcinoma (HCC) high risk factors that warrant screening
- Added surveillance after treatment completed for known liver cancer
- For Adults, added recommendations for CT, Abdomen and MRI, Abdomen to the initial screening pathway for individuals with a nondiagnostic or suboptimal ultrasound

GI Tract, Upper and Lower

- Added a recommendation for CT Colonography if stool DNA (Cologuard) positive and colonoscopy not feasible

Imaging

Bone & Joint



Imaging, Shoulder

-  New indications added to reflect American College of Radiology (ACR):
 - Rotator cuff failure after joint replacement
 - Joint infection after arthroplasty
- Added recommendation for 3D Rendering for treatment planning under aseptic loosening of prosthesis or cement, joint infection, and rotator cuff failure after prior joint replacement

Imaging

Bone & Joint



Usability updates to the following subsets for when an X-ray was not performed:

- Imaging, Ankle
- Imaging, Elbow
- Imaging, Hip
- Imaging, Knee
- Imaging, Wrist

X-ray diagnostic for etiology of symptoms or findings *Required*

Choose an answer to continue



Choose one: *Required*

Imaging

Chest & Heart



Imaging, Cardiac, Stress

- Added a recommendation for stress echocardiogram to assess myocardial viability
- Added myocardial scintigraphy with bone-avid radiotracers with SPECT/CT for assessing suspected or known cardiac amyloidosis

Imaging, Chest, Non-Cardiac

- Added an indication to screen for lung metastases in patients with liver cancer

Cardiac Imaging, Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)

- Changed recommendation from limited evidence to a full recommendation for coronary calcium screening for patients who are borderline or intermediate risk for coronary disease
- Added recommendation for cardiac CT for known or suspected coronary artery anomaly

Imaging

Chest & Heart



Positron Emission Tomography (PET), Cardiac

- Added indication for cardiac infection and inflammation
- Added recommendation for cardiac PET/CT as an equivalent test to cardiac PET without a CT

Imaging

General



Imaging, Breast

- Added dense breast tissue as independent breast cancer risk factor
- Added intermediate risk for breast cancer as a new risk category
- Added imaging for new genetic mutations NF1, BARD1, RAD51C, and RAD51D that can increase risk for breast cancer

Imaging

Head & Neck



Imaging, Carotid



- Added recommendations CTA or MRA of carotid arteries for asymptomatic patients with carotid bruit and other indications and preoperative evaluation of patients undergoing mechanical thrombectomy
- Expanded list of atherosclerotic risk factors that warrant US screening for patients at least 65 years of age
- Added an indication for follow-up US imaging after endarterectomy

Durable Medical Equipment

Durable Medical Equipment



New Subset: Stretching Devices, Upper Extremity

- Includes initial and ongoing criteria for upper extremity stretching devices for management of contracture
- Includes:
 - Dynamic stretch or low-load prolonged-duration stretch (LLPS) devices (E1800, E1802, E1805, E1825, E1840) for shoulder, elbow, forearm, wrist, and finger motions
 - Static progressive stretch (SPS) devices (E1801, E1806, E1818, E1841) for shoulder, elbow, forearm, and wrist motion

Durable Medical Equipment



HCPCS codes provided within criteria to support accurate selection

Noninvasive bone growth stimulator device requested, Choose one: Required

Low-intensity pulsed ultrasound (LIPUS) (E0760)

Non-spinal electrical stimulator (E0747)

Spinal electrical stimulator (E0748)

None of the above

Choose an answer to continue

Type of orthoses for osteoarthritis, Choose one: Required

Prefabricated, off-the-shelf orthosis (minimal modifications) (L1812, L1821, L1833, L1852)

Prefabricated, custom-fitted orthosis (substantial modifications) (L1810, L1820, L1832, L1845)

Custom-fabricated orthosis (L1846)

Lower extremity orthosis, not otherwise specified (L2999)

None of the above

Choose an answer to continue

Durable Medical Equipment

Orthoses, Lower Extremity, Knee



Added

- Initial or replacement request for components or features alone or as part orthosis request
- Indication and recommendations when there is non-fixed knee contracture and patient is non-ambulatory
- Criteria for weight > 300 pounds and recommendations for heavy-duty components or features
- Indications and recommendations for lower extremity orthoses not otherwise specified (L2999)
- Myoelectric device, knee (evidence does not support)



Revised

- Arthritis indication to include multicompartamental osteoarthritis criteria and recommendations
- When replacement request is due to significant change in patient's condition, the criteria has been restructured to do an initial review based on new clinical presentation

Durable Medical Equipment

Orthoses, Lower Extremity, Knee-Ankle-Foot (KAFO) and Ankle-Foot (AFO)



- Criteria and recommendations for microprocessor stance-controlled knee-ankle-foot orthosis (KAFO) (L2006) when custom fabricated KAFO is requested for instability



Durable Medical Equipment

Orthosis, Thoracic, Lumbar, and Sacral Spine



Added indication

- Pectus carinatum, with criteria for Custom-fabricated thoracic, pectus carinatum orthosis, sternal compression (L1320)

Revised indications

- Idiopathic scoliosis indication expanded to include specific criteria for
 - Infantile idiopathic scoliosis (0 to 4 years)
 - Juvenile idiopathic scoliosis (4 to 10)
 - Adolescent idiopathic scoliosis (≥ 10 years)

Durable Medical Equipment

Orthosis, Upper Extremity



Content changes for enhanced usability

- Updated prerequisite criteria (Instruction in use, PT/OT, HEP) to address scenarios where they may be either planned, ongoing, contraindicated, not indicated, or not appropriate
- Clarified goals of orthotic management based on the clinical condition or anatomy

+ Added indications

- Myoelectric orthosis, elbow-wrist-hand (L8701) and Myoelectric orthosis, elbow-wrist-hand-finger (L8702) (Limited Evidence)
- Orthosis not otherwise specified (L3999)
- Fracture orthoses (humeral, radial, ulnar, wrist, and hand)
- Custom-fabricated orthosis, dynamic flexor hinge (L3900, L3901)
- Prefabricated flexion glove with elastic finger control (L3912)



Revised

- Removed contracture indication which is now included as one of the goals of orthotic management
- Removed the distinction "static" and "dynamic" when selecting an orthosis

Durable Medical Equipment



Bone Growth Stimulators, Noninvasive

- Noninvasive electrical stimulation (capacitive coupling or pulsed electromagnetic field) changed to Non-spinal electrical stimulator (E0747) AND Spinal electrical stimulator (E0748)

Non-spinal electrical stimulator (E0747)

- Removed contraindication of fracture, not tumor related when there is failed surgical fusion (non-spinal)
- Added fracture gap size ≤ 1 cm, when there is fracture nonunion (not spinal or cranial)

Spinal electrical stimulator (E0748)

- Added pre-op diagnoses of spinal stenosis and disc herniation for post-initial single-level spinal fusion
- For delayed union or nonunion risk factors, removed requirement of HbA1c $> 7\%$ and added history of delayed union or nonunion
- Changed time frame for adjunctive use post-revision spinal fusion from ≥ 6 months to 6 to 9 months and ≥ 9 months post- surgery
- Recommendation for adjunctive use when 6 to 9 months post-revision spinal fusion is now off-label. Adjunctive use ≥ 9 months post- surgery remains a full recommendation.

Durable Medical Equipment



Bone Growth Stimulators, Noninvasive (cont.)

Low-intensity pulsed ultrasound (LIPUS) (E0760)

- Added confirmation that fracture gap size is < 1 cm, when there is fracture nonunion (not spinal or cranial)
- Removed HbA1c $> 7\%$ from the diabetes mellitus risk factor for delayed union or nonunion
- Added high energy trauma as a risk factor for delayed union or nonunion when there is a fresh fracture

Durable Medical Equipment



Enteral and Parenteral Nutrition Therapy

Initial request

- Revised conditions that might require parenteral or enteral nutritional support to reflect clinical presentation instead of specific diagnoses
- Criteria for pump feeding changed to gravity feeding not indicated, inadequate, or not tolerated

Ongoing request

- Added formula and solutions to supplies in ongoing request recommendations
- Changed physician evaluation at least every three months to patient tolerating enteral or parenteral nutrition

Replacement request

- Added option for IV pole replacement with applicable HCPCs added

Molecular Diagnostics

Molecular Diagnostics



Global changes

- The Clinical Evidence Summary (CES) papers have been removed from all subsets

Retired all CES only subsets

- Cancer Antigen 19-9 (CA 19-9) (CES only)
- Cancer Antigens 27.29 and 15-3 (CA 27.29 and CA 15-3) (CES only)
- HLA Genotyping for Narcolepsy (CES only)
- HLA-DRB1 Genotyping for Juvenile Idiopathic Arthritis (JIA) (CES only)
- VEGF and VEGFA Testing for Bevacizumab Response (CES only)
- VeriStrat® (CES only)
- Whole-Genome Next-Generation Sequencing (WGS) for Oncology (CES only)

Molecular Diagnostics



Multi-Gene Panels for Hereditary Breast Cancer Syndromes and

BRCA1 and BRCA2 in Hereditary Cancer

- Diagnostic or Confirmatory testing pathway: Changed age < 60 to ≤ 65 when personal history of breast cancer and there is a diagnosis of breast cancer, regardless of if there is a known breast cancer-associated inherited mutation in the family

BRCA1 and BRCA2 in Hereditary Cancer

- Added criteria for testing when there is a family history of a specific type of prostate cancer

Pharmacogenomic testing in NSCLC

- Evidence supports testing of NRG1 in a targeted multi-gene panel



Molecular Diagnostics



Lynch Syndrome (LS)

- When sequence analysis had not yet been performed a reflexed deletion/duplication test can be mutually recommended
- Removed single gene sequence analysis (for MLH1 and MSH2) for previously untested patients
- Added LS-related mutation is detected in tumor tissue and subsequent testing is requested for the same mutation in non-tumor (germline) sample
- Updated to ensure all possible testing options and combinations are available

Multi-Gene Panels for Hereditary Colorectal Cancer Syndromes

- Added recommendations for POLD1 and POLE genes on multi-gene panels
- Added criteria for testing when the likelihood of a relevant mutation is $\geq 2.5\%$ to $< 5\%$ -- limited evidence recommendation
- Removed recommendation for targeted multi-gene panel for hereditary colorectal cancer syndromes (APC and MUTYH)
- Added recommendation for testing when at least 10 adenomatous polyps or 2 hamartomatous polyps are found
- Added testing when an initially-suspected hereditary colorectal cancer syndrome and known familial mutation are ruled out in a patient with colorectal cancer or polyposis

Molecular Diagnostics

Prostate Cancer



Decipher® for Prostate Cancer

- Changed limited evidence to full recommendation for NCCN risk group unfavorable intermediate

Oncotype DX® Genomic Prostate Score (GPS) Assay

- Changed subset name Oncotype DX® Prostate Cancer Assay to Oncotype DX® Genomic Prostate Score (GPS) Assay
- Changed limited evidence to full recommendation for NCCN risk group low or favorable intermediate
- Changed evidence does not support to limited evidence recommendation for NCCN risk group unfavorable intermediate

Prolaris® for Prostate Cancer

- Removed criteria related to radical prostatectomy or transurethral resection of the prostate
- Changed evidence does not support to limited evidence recommendation for NCCN risk group unfavorable intermediate or high

Molecular Diagnostics



Multi-Gene Panels for Autism Spectrum Disorder (ASD)

- Added criteria to require the ASD to be non-syndromic

Beta globin (HBB) testing for Beta-thalassemia and Sickle Cell Disease

- Updated testing strategy for familial mutation based on affected relatives
- Updated diagnostic or confirmatory testing strategy to include testing to determine if one or both alleles contain mutations
- Updated criteria and recommendations based on prior tests performed
- Added prenatal testing of the fetus when only the biological mother has a known mutation and father not available for testing

Hereditary Cardiomyopathy

- Changed subset name Genetic Testing for Hereditary Cardiomyopathy to Hereditary Cardiomyopathy
- Removed criteria when used **only** to direct genetic testing of first-degree relative for individuals diagnosed with cardiomyopathy suspected to be hereditary

Specialty Referral

Specialty Referral



Adrenal disorders

- Added History of extra-adrenal malignancy for a new adrenal mass and Suspicious imaging for adrenocortical carcinoma for new adrenal mass or incidentaloma
- Revised size recommendations so that all new adrenal masses or incidentalomas ≥ 4 cm are recommended for referral
- Removed hormonal evaluations as a requirement prior to referral

Carotid disorders

- Added option to refer patients with carotid stenosis, carotid dissection, or unstable carotid plaque to vascular medicine
- Added option to refer patients with carotid dissection to a neurologist

Gastrointestinal (GI) Cancer Screening or Surveillance

- Added options for colorectal cancer screening if 3rd degree relative diagnosed with colorectal cancer at any age or if sDNA test (Cologuard) positive

Specialty Referral



Neck Disorders

- Moved indication for cervical spondylosis from Spinal Cord and Nerve Root Disorders subset

Spinal Cord and Nerve Root Disorders

- Removed indication whiplash from Neck Disorders
- In Spinal Cord and Nerve Root Disorder, inclusion of new finding for myelopathy – myelomalacia by imaging

Sleep apnea

- Renamed from sleep apnea to Sleep-Related Breathing Disorders (SRBD)
- Restructured criteria when an SRBD is suspected
- Restructured criteria to allow specialist referral following a negative or nondiagnostic sleep study in addition to referral following abnormal sleep study results
- Included follow-up with a specialist during treatment for an SRBD
- Added hypoglossal nerve stimulator as a reason for follow-up with a specialist during or after treatment for an SRBD

Q&A

Optum

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2025 Optum, Inc. and/or one of its subsidiaries. All rights reserved.